Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1802665 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $35.86Day +0.25%Mkt cap $2.1BP/E (FY) 13.2×1Y +1.2%Off 52W high −12.3%Vol (1Y) 44.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesUNDEMANDING · 0.1% growth |
| Short interest8.8% of sh out |
| Days to cover6.8d |
| 13F net flow (QoQ)+11.62% |
| Top-10 13F concentration47.7% |
| Next report (est.)2026-08-06 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)13.2× |
| Sales (TTM)$899.1M |
| Earnings (TTM)$145.6M |
| ROE20.8% |
| Net margin18.3% |
| ROIC48.8% |
| YTD−4.2% |
| 1Y+1.2% |
| 3Y+1.4% |
| 5Y+36.8% |
| Since incept. (ann.)−0.7% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)44.1% |
| Ann. volatility (3Y)49.0% |
| Sharpe (1Y)0.23 |
| Sharpe (3Y)0.27 |
| Max drawdown (1Y)−34.5% |
| Max drawdown (3Y)−50.8% |
| Beta (3Y vs SPY)1.40 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 7.1M | $198M | 12.22% | −0.3% |
| FMR LLC | 3.2M | $88M | 5.46% | +1.4% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.7M | $76M | 4.69% | new |
| AMERICAN CENTURY COMPANIES INC | 2.1M | $59M | 3.64% | +14.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $59M | 3.63% | new |
| DIMENSIONAL FUND ADVISORS LP | 2.1M | $58M | 3.59% | +13.4% |
| LSV ASSET MANAGEMENT | 2.0M | $57M | 3.50% | +22.2% |
| SG Americas Securities, LLC | 2.0M | $57M | 3.49% | +109.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | $0.55 | −29.5% | $215.4M | +16.6% |
| 2025-12-31 | 2026-02-24 | — | — | $243.8M | +21.1% |
| 2025-09-30 | 2025-11-04 | $0.87 | +10.1% | $239.5M | +28.7% |
| 2025-06-30 | 2025-08-05 | $0.68 | +240.0% | $200.5M | +16.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Rare Neurological Diseases 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| EPS growth 3Y−3.0% |
| Sales growth 3Y25.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
